Results from the REFLECT II Trial reported at TCT Connect

(Cardiovascular Research Foundation) The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news